He holds so much of both, from his perspective as an investor in both it would only make sense if both companies had fair valuations and could perform better as one.
If he only held CHM, then I'm sure a TO at 10x current valuation might appeal to the investor in him (probably not to the rest of the Imugene BOD nor large SHs).
The only way I could see it happening is if ALA joined with CHM first, because the CD19 NK cell asset would be a reasonable target for IMU (already in pre-clinical work). But I doubt that merger would happen any time soon.
IMU + ALA - maaayyybe. IMU + CHM - tell him he's dreaming.
CHM Price at posting:
3.1¢ Sentiment: Buy Disclosure: Held
(20min delay)